230 results about "Drug vehicle" patented technology

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof. The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.

The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Implantable drug delivery systems target delivery of small volumes of drugs to specific tissues. In some cases, a drug delivery system includes an implantable osmotic pump connected to a drug-containing housing, with that housing connected to a needle, cochlear implant or other type of component for ultimate delivery to the target tissue. In some implementations, a subcutaneous port receives a fluid from an external pump. The port is connected to a needle or other component for delivery of one or more drugs to the target tissue. Both solid and liquid drug formulations can be used. In embodiments using solid drugs, a separate drug vehicle (such as saline) can be used to dissolve a portion of the solid drug, with the drug-loaded vehicle then delivered to the target tissue.

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

The invention relates to the field of high-molecular porous materials and particularly relates to a preparation method of porous chitosan-based microspheres for medicine carriers, adsorption and separation, hemostasis and wound dressing. The preparation method comprises the following steps: (a) respectively preparing solidification liquid, an emsulsifying-agent solution and a diluted-acid solution of pelletizing materials and precooling the solidification solution to minus 20 DEG C; (b) dripping the chitosan diluted-acid solution into the emsulsifying-agent solution, homogenizing and stirring to form emulsion; and (c) carrying out thermally-induced phase separation on the emulsion under the temperature ranging from minus 60 DEG C to minus 10 DEG C, adding precooled solidification liquid, carrying out reverse-phase regeneration and thus obtaining the chitosan-based porous microspheres. The preparation method has the beneficial effect that the surfaces and the inner parts of the porous microspheres have porous structures with communicated heights.

A chitosen-quaternary ammonium salt nanoparticle as the carrier of protein-type medicine is prepared through dissolving chitosan-quaternary ammonium salt in distilled water, stirring while adding solution of sodium tripolyphosphate, cross-linking, centrifugal separation, and freeze drying. It has long relesing period (6 days).

The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.

The preparation method includes the following steps: modifying hepatic target compound onto degradable polymer (chitosan, polylysine, glucosan, agar, polyglutamic acid-benzyl ester, polyalanine) with biological compatibility, and adopting ion exchange or ultrasonic emulsification process to obtain the invented nano hepatic target bio-degradable medicine carrier material. The hepatic target nano particle solution has good target performance for liver, the medicine enriched rate in the liver can be up to 75%, and its slowly-released administration can be up to above 15 days.

In accordance with the present invention, novel formulations have been developed which are much more effective for the delivery of hydrophobic drugs to patients in need thereof than are prior art formulations. Invention formulations are capable of delivering more drug in shorter periods of time, with reduced side effects caused by the pharmaceutical carrier employed for delivery.

An anticancer high-molecular precursor medicine C-Spacer-P, where P is high- molecular pectin, C is an anticancer medicine containing amino radical or hydroxy radical, and Spacer is the spacing radical, is prepared by bonding the amino or hydroxy of an anticancer medicine with the hydroxy, carboxy, or hydroxymethyl of high- molecular pectin via spacing radical. It is an injection suitable for the solid cancer, and cancerous ascites or hydrothorax.

Vehicle and method is disclosed for treating and / or preventing skin disorders such as acne vulgaris and which exfoliates healthy skin by a topical application. The vehicle is a formulation incorporating hypohalous acid in a suitable pharmaceutical compound. The topical application comprises administering and scrubbing a therapeutically effective amount of hypohalous acid in the vehicle. The hypohalous acid may be hypochlorous acid, hypobromous acid, or hypoiodious acid. The suitable pharmaceutical vehicles include water, solutions, cleansers, lotion, cream, paper facial masks, and gels. The scrubbing action on the skin is exerted by a mechanic tool, such as hand, cloth towel, sponge, brush, and spraying device. Methods of preparing and compounding the vehicle for topical application and of its use are also set forth.

The invention relates to a monolayer graphite oxide and magnetic ferroferric oxide nano-particle composite hybrid material, and a preparation method and application thereof. The monolayer graphite oxide and magnetic ferroferric oxide nano-particle composite hybrid material is made from raw materials of monolayer graphite oxide material and a mixture of bivalent malysite and ferric malysite by a chemical deposition method. The preparation method comprises the steps as follows: the monolayer graphite oxide is dispersed in sodium hydroxide aqueous solution to obtain monolayer graphite oxide with sodium carboxylate; then ion exchange is carried out on the mixture of monolayer graphite oxide and the bivalent malysite and the ferric malysite under the protection of nitrogen; the processed mixture is deposited by sodium hydroxide solution after excessive malysite is removed to obtain a solid product; and the solid product is separated out and dried to obtain superparamagnetic monolayer graphite oxide and ferroferric oxide nano-particle composite hybrid material. The material is used for loading drug to obtain an efficient controllable targeted drug carrier with the magnetic property of pH response. The invention has wide application prospect in the aspects of multiple targeted drug delivery, and the separation, the purification, the inspection and the like of nuclear magnetic resonance contrast medium, DAN, protein, etc.

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

A coated medicine layer on the scaffold in arteria coronaria for preventing angiostenosis is prepared through dissolving the aliphatic polylactone and its copolymer is solvent, adding taxusol, stirring while dissolving, filtering, coating on the scaffold, evaporating the solvent, removing the solvent for 48 hr under vacuum, and disinfecting by epoxy ethane.

The invention discloses a conjugate of fatty aminoacyl alexan, preparation and application in anti-tumor thereof. The invention also discloses a pharmacosome of the conjugate of fatty aminoacyl alexan, preparation thereof, and its applicant in anti-tumor and preparation of target medicine material of microemulsion, lipid medicine carrier. In comparison with alexan, the inventive conjugate of fatty aminoacyl alexan has a strong transmembrane ability, high bioavailability, long halflife, and amphipathic nature. It is demonstrated that the inventive compound and pharmacosome have great anti-tumor activity.

A stable suspension formed of a plurality of water particles each of which is encapsulated with an amorphous silica-based material, where that plurality of encapsulated water particles is dispersed in a continuous phase formed of one or more carbon-containing materials, where the stable suspension does not include added emulsifiers. A method to prepare such stable suspensions. Personal care products comprising Applicant's stable suspensions, including skin protectants, sunscreens, moisturizers, vehicles for medicaments, antiperspirants, deodorants, pressurized products such as aerosol products, vehicles for skin treatment products and vehicles for makeup, area of the eye, lip products, mascara and color cosmetic products.

A hair treatment composition for topical application to the skin and / or hair, comprising partially hydrolyzed fucoidan and a pharmaceutical carrier. The composition may contain further additives. The carrier may be hydrophyllic or anhydrous. The composition may also include natural components such as honey and / or mangosteen. The composition may also include flavonoids, analgesics, radiation protecting agents, and / or anti-oxidants.

The present invention includes a method for reducing viral, bacterial, protozoan, fungal and other parasitic contamination from a biological solution. Biological solutions include, but are not limited to, solutions comprising blood, a blood component, cell culture or a component of a cell culture. In accordance with the present invention, there is provided, a method of inactivating a pathogen in blood or blood product in a container, comprising contacting at least one of said blood, blood product and container with a composition of the present invention. In accordance with the present invention, there is provided, a medical device comprising at least a surface treated with an anti-pathogenic composition of the present invention or containing at least an anti-pathogenic composition of present invention. In accordance with the present invention, there is provided, an anti-pathogenic composition for use in disinfecting fluids and biological tissues and surfaces contaminated with fluids and / or biological tissues, which comprises an anti-pathogenic amount of at least one quaternary ammonium compound in association with an acceptable carrier. A preferred anti-pathogenic composition of the present invention further comprises a bisguanidine compound. In accordance with the present invention, there is provided a method for inhibiting in vitro or ex vivo infection or replication of human immunodeficiency virus in a biological fluid, comprising treating said biological fluid with an effective inhibiting amount of a bis-guanidine compound or a derivative thereof, and at least one quaternary ammonium compound in combination with a pharmaceutically carrier, such as DMSO.